Every AI newsletter,Essence Securities issued a research report on August 30, stating that it maintains Wuliangye (000858.SZ, latest price: 207 yuan) Buy-A rating. The reasons for the rating mainly include: 1) Event: the company disclosed the 2021 semi-annual report; 2) Both products and channels have improved, and direct sales have achieved substantial growth; 3) The series of wines persisted in reforms and achieved results, with both volume and price rising; 4) Gross profit margin and expense ratio Decline, the cash flow position is excellent, and the brand potential is strengthened. Risk warning: the increase in the price fluctuations of classic Wuliangye, and the increase in the high-end competition of 1,000 yuan may lead to the possibility.
AI comment: Wuliangye has received the attention of 9 brokerage research reports in the past month, buying 8 companies, with an average target price of 320.22 yuan, which is 113.22 yuan higher than the latest price of 207 yuan, and the target average price has increased by 54.69%.
Every Jing Toutiao (nbdtoutiao)——The first week of centralized procurement of clinical test reagents: when the policy first came out, the sector evaporated hundreds of billions of dollars in a single day, the representatives of the manufacturers were “profusely sweating”, and the agents called the industry changed.
(Reporter Wang Xiaobo)
Disclaimer: The content and data in this article are for reference only and do not constitute investment advice. Please verify before use. According to this operation, at your own risk.
Copyright Notice
1This article is the original work of “Daily Economic News”.
2
Without the authorization of “Daily Economic News”, it may not be used in any way, including but not limited to reprinting, extracting, copying or creating mirror images, etc., offenders must be investigated.
3Copyright cooperation telephone: 021-60900099.